ReviewJournal for immunotherapy of cancer2022
MRI techniques for immunotherapy monitoring.
Review in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Intravoxel incoherent motion diffusion-weighted imaging for early response stratification of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor in renal cell carcinoma: an exploratory study.Japanese journal of radiology · 2026Article
- Article
- Article
- Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03.Neuro-oncology practice · 2026Article
- Biliary tract neoplasms from common to rare: diagnosis, assessment, and management.Abdominal radiology (New York) · 2026Review
- [Pseudoprogression after start of immunotherapy].Radiologie (Heidelberg, Germany) · 2026Review
- Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response.Journal for immunotherapy of cancer · 2025Article
- Tumor-Targeting TACS omega · 2025Article
- Immunotherapy and targeted therapy for high grade gliomas: current and future directions.Journal of neuro-oncology · 2025Review
- Quantitative response assessment of combined immunotherapy in a murine melanoma model using multiparametric MRI.European radiology experimental · 2025Article
- Improved Tumor Blood Flow Enhances the Abscopal Effect: Preclinical Assessment in Mice Treated with Combined Radiation and PD-1 Blockade Therapy.bioRxiv : the preprint server for biology · 2025Article
- Let UNet Play an Adversarial Game: Investigating the Effect of Adversarial Training in Enhancing Low-Resolution MRI.Journal of imaging informatics in medicine · 2025Article
- Review
- Imaging antigen processing and presentation in cancer.Immunotherapy advances · 2025Review
- Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy.Journal of personalized medicine · 2024Article
- CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials.Cancer metastasis reviews · 2024Review
- Engineered SPIONs functionalized with endothelin a receptor antagonist ameliorate liver fibrosis by inhibiting hepatic stellate cell activation.Bioactive materials · 2024Article
- Correlation of KJournal for immunotherapy of cancer · 2024Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following VEGFR-2 and PD-1 blockade in a colon cancer model.Journal of translational medicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
MRI is a widely available clinical tool for cancer diagnosis and treatment monitoring. MRI provides excellent soft tissue imaging, using a wide range of contrast mechanisms, and can non-invasively detect tissue metabolites. These approaches can be used to distinguish cancer from normal tissues, to stratify tumor aggressiveness, and to identify changes within both the tumor and its microenvironment in response to therapy. In this review, the role of MRI in immunotherapy monitoring will be discussed and how it could be utilized in the future to address some of the unique clinical questions that arise from immunotherapy. For example, MRI could play a role in identifying pseudoprogression, mixed response, T cell infiltration, cell tracking, and some of the characteristic immune-related adverse events associated with these agents. The factors to be considered when developing MRI imaging biomarkers for immunotherapy will be reviewed. Finally, the advantages and limitations of each approach will be discussed, as well as the challenges for future clinical translation into routine clinical care. Given the increasing use of immunotherapy in a wide range of cancers and the ability of MRI to detect the microstructural and functional changes associated with successful response to immunotherapy, the technique has great potential for more widespread and routine use in the future for these applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.